SRR1476186
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.407
- MYOGENESIS+0.345
- PANCREAS_BETA_CELLS+0.340
- ANGIOGENESIS+0.317
- ALLOGRAFT_REJECTION+0.311
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.294
- COAGULATION+0.264
- APICAL_SURFACE+0.250
- ESTROGEN_RESPONSE_LATE+0.206
- KRAS_SIGNALING_UP+0.202
Top 10 suppressed
- PROTEIN_SECRETION-0.534
- UNFOLDED_PROTEIN_RESPONSE-0.507
- MYC_TARGETS_V2-0.493
- G2M_CHECKPOINT-0.491
- MITOTIC_SPINDLE-0.464
- E2F_TARGETS-0.457
- MTORC1_SIGNALING-0.422
- MYC_TARGETS_V1-0.422
- PI3K_AKT_MTOR_SIGNALING-0.365
- ANDROGEN_RESPONSE-0.347
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1440962 | GTEX | — | 0.925 |
| 2 | MDT-AP-1204 | Med | Medulloblastoma | 0.916 |
| 3 | SRR1322419 | GTEX | — | 0.914 |
| 4 | SRR1397073 | GTEX | — | 0.914 |
| 5 | TCGA-49-4512-01A-21R-1858-07 | — | cohortA1 | 0.914 |
| 6 | SRR1457551 | GTEX | — | 0.913 |
| 7 | SRR1352554 | GTEX | — | 0.909 |
| 8 | SRR598276 | GTEX | — | 0.907 |
| 9 | SRR1473654 | GTEX | — | 0.906 |
| 10 | SJEPD001523_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.407 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.345 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.317 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.311 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.294 | Inavolisib | — uncovered |
| COAGULATION | 0.264 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.206 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.202 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.196 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.132 | Inavolisib | — uncovered |
| COMPLEMENT | 0.105 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.078 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.071 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.063 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.027 | Inavolisib | — uncovered |
| APOPTOSIS | 0.019 | Idelalisib | — uncovered |